If the CBD product is broad-spectrum, it will have only non-detectable levels of THC (meaning the amount is so small it doesn’t show up on a lab report). Here we report the first phase III placebo-controlled study of the efficacy of the endocannabinoid system modulator delta-9-tetrahydrocannabinol (THC)/cannabidiol (CBD) oromucosal spray (USAN name, nabiximols